148220 people have viewed this drug in the last 60 days
Updated 2025-12-07
| Last Update | 2023-02-28 |
| Register Year | 2016 |
| Product Type | Human |
| Drug Type | NCE |
| Scientific Name | OLMESARTAN MEDOXOMIL,HYDROCHLOROTHIAZIDE,AMLODIPINE BESILATE |
| Trade Name | SEVIKAR HCT 40/5/25MG FILM COATED TABLET |
| Strength Unit | mg |
| Pharmaceutical Form | Film-coated tablet |
| Administration Route | Oral use |
| Atc Code1 | C09CA08 |
| Atc Code2 | |
| Size | 0 |
| Size Unit | |
| Package Types | Blister |
| Package Size | 28 |
| Legal Status | Prescription |
| Product Control | Uncontrolled |
| Distribute Area | Pharmacy |
| Public price | $110.95 |
| Shelf Life | 48 Months |
| Marketing Company | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO |
| Marketing Country | Saudi Arabia |
| Manufacture Name | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO |
| Manufacture Country | Saudi Arabia |
| Secondry package manufacture | |
| Main Agent | Saudi Arabian Japanese Pharmaceutical Co. Ltd. |
| Secosnd Agent | |
| Third Agent | |
| Visits | 148220 |
Do not forget, after purchasing the medicine, help us determine the price more accurately, press the button below and adjust the price directly
| Name | Price | Visits | Updated |
|---|---|---|---|
| SEVIKAR HCT 40/10/25MG FILM COATED | $124.2 | 185411 visits | 2023-02-28 |
| SEVIKAR HCT 40/10/12.5MG FILM COATED&nbs | $124.2 | 162714 visits | 2023-02-28 |
| SEVIKAR HCT 40/5/25MG FILM COATED | $110.95 | 148220 visits | 2023-02-28 |
| SEVIKAR HCT 40/5/12.5MG FILM COATED | $110.95 | 286266 visits | 2023-02-28 |
| SEVIKAR HCT 20/5/12.5MG FILM COATED | $86.85 | 295003 visits | 2023-02-28 |
| SEVITENSE PLUS 20/5/12.5 MG FILM COATED& | $73.8 | 22032 visits | 2022-11-03 |
| SEVITENSE PLUS 40/5/12.5 MG FILM COATED& | $94.3 | 209323 visits | 2022-11-03 |
| SEVITENSE PLUS 40/10/25 MG FILM COATED&n | $105.55 | 26694 visits | 2022-11-03 |
| SEVITENSE PLUS 40/5/25 MG FILM COATED&nb | $94.3 | 188081 visits | 2022-11-03 |
| SEVITENSE PLUS 40/10/12.5 MG FILM COATED | $105.55 | 291584 visits | 2022-11-03 |